Previous 10 | Next 10 |
Received Priority Review and Acceptance for Filing of the NDA for Omaveloxolone for Treatment of Patients with Friedreich’s Ataxia Provides Update from FDA Mid-Cycle Communication Meeting on Omaveloxolone for Patients with Friedreich’s Ataxia An...
Reata Pharmaceuticals ( NASDAQ: RETA ) is scheduled to announce Q2 earnings results on Monday, August 8th, before market open. The consensus EPS Estimate is -$1.97 (-49.2% Y/Y) and the consensus Revenue Estimate is $1.46M (-34.2% Y/Y). Over the last 2 years, RETA has...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the second quarter e...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022. “We...
Stanley Druckenmiller’s 13F portfolio value decreased from $2.93B to $2.31B this quarter. Duquesne added Teck Resources and Coterra Energy while dropping Alphabet, Carvana, and Palo Alto Networks. They also added a large short position in S&P 500 index through Puts. The...
Plano, Texas-based Reata Pharmaceuticals (NASDAQ:RETA) is trading higher for the second straight session on Friday as Citi welcomes the company’s recent announcement of the FDA’s Priority Review granted for its marketing application for omaveloxolone in Friedreich's ataxia ...
The U.S. Food and Drug Administration (FDA) granted priority review to Reata Pharmaceuticals' (NASDAQ:RETA) omaveloxolone to treat patients with Friedreich's ataxia (FA). FA is a rare genetic, progressive and degenerative neuromuscular disorder. The FDA is expected to make a decision by Nov. ...
Friedreich’s Ataxia is a Rare, Progressive, Life-Shortening, Neuromuscular Disease that Affects Approximately 5,000 Patients in the United States Application Assigned a PDUFA Date of November 30, 2022 If Approved, Omaveloxolone Would Become the First A...
Reata Pharmaceuticals, Inc. (RETA) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Warren Huff – Chief Executive Officer Manmeet Soni – President Colin Meyer – Chief Innovation Officer Seemi Khan – Chief Medical officer Dawn Bir ȁ...
The following slide deck was published by Reata Pharmaceuticals, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Reata Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...